Summary

  • Moderna completed $3 billion of 0.00% convertible senior notes with an initial conversion price of $210.5839, but that price does not create a continuous early-conversion right.
  • The holder’s quarterly stock-price condition is initially $315.88—150% of the conversion price for at least 20 of 30 trading days in the preceding quarter—and first applies after the quarter ending 31 December 2026.
  • The issuer’s optional-redemption condition is initially lower at $273.76, or 130% of the conversion price, but Moderna generally cannot use it before 6 September 2029 and still must elect to issue a notice.
  • A redemption call opens a separate conversion path for the called notes. From 1 December 2031, holders may convert without satisfying the earlier conditions.
  • The separate capped calls start at the same $210.5839 strike and stop at $392.6175. That ceiling belongs to Moderna’s dealer contracts, not to noteholders.

A conversion price is not permission to convert

Moderna’s 1 September Form 8-K confirms the completion of $3 billion in 0.00% convertible senior notes due 1 March 2032. The full $400 million purchaser option was exercised. Each $1,000 of principal initially corresponds to 4.7487 shares, equivalent to a conversion price of $210.5839.

Market shorthand tends to stop there. It treats $210.58 as the line at which the debt becomes stock. The indenture says something narrower. Until the business day immediately before 1 December 2031, holders may convert only when one of several conditions opens a window. Crossing the conversion price by itself is not one of them.

This distinction matters because price and authority are separate variables. The conversion rate determines the amount of stock-equivalent value in the instrument. The conversion conditions determine when the holder may exercise that value. Moderna then chooses whether to deliver cash, shares or a combination, subject to the contract. One number therefore does not tell the reader whether conversion is available, whether it will occur or how it will be settled.

The holder’s first stock-price door is $315.88

The most visible early-conversion route is a quarterly price test. During a calendar quarter beginning after the quarter ending 31 December 2026, holders may convert if Moderna’s closing price was at least 150% of the then-current conversion price on at least 20 trading days, not necessarily consecutive, in a 30-consecutive-trading-day period ending on the last trading day of the preceding quarter.

At the initial unadjusted conversion price, the arithmetic is $210.5839 multiplied by 1.5, or $315.87585. Rounded to cents, the first holder gate is $315.88. That is 121.25% above the $142.77 stock price used when the notes were priced.

Neither comparison is a target. The $315.88 amount can move if the conversion rate is adjusted, and a market price above it on one day does nothing. The contract needs 20 qualifying days inside the defined observation period. A passing result opens the following calendar quarter; it does not force a holder to convert and does not make the window permanent.

There are other doors. A holder may gain a five-business-day conversion period after a ten-day note-trading-price test, may convert notes called for redemption during the relevant call period, or may convert upon specified corporate events. These routes show why the instrument cannot be reduced to one stock chart. Each state has its own evidence.

Moderna’s later call test is lower—but belongs to Moderna

The issuer’s optional-redemption rule produces the counterintuitive step. Moderna generally cannot redeem the notes before 6 September 2029, apart from a cleanup redemption. After that date and before the final pre-maturity exclusion period, it may call all or part of the notes if its stock has traded at least at 130% of the then-current conversion price on 20 of 30 trading days ending immediately before the notice.

Using the initial price, 130% equals $273.75907, or $273.76. That is $42.12 below the holder’s initial quarterly gate. The lower number does not hand Moderna an earlier right. Its clock starts almost three years later, and the price record only permits a call—it does not issue one.

If Moderna does call notes, the called amount gains a conversion route during the redemption period. The structure therefore contains an asymmetry. A stock path that is insufficient to pass the holder’s 150% quarterly condition could, after September 2029, satisfy the issuer’s 130% call test. Moderna could then decide whether to redeem, and that decision could let holders of the called notes convert.

Control remains bounded. A partial optional redemption must leave at least $100 million principal outstanding and not called. A separate cleanup rule can permit redemption of all remaining notes when less than $100 million is outstanding. Both are contractual states, not evidence that management intends to act.

December 2031 removes the earlier gates

On 1 December 2031, the map changes again. From that date until the close of business on the second scheduled trading day immediately before maturity, holders may convert without satisfying the quarterly price test, note-trading-price test, redemption call or corporate-event condition.

This open window is short relative to the note’s life. It preserves a final choice before the 1 March 2032 maturity, when the principal claim must otherwise be addressed. A holder still does not control the settlement medium: Moderna retains the election to use cash, shares or both.

The issue is zero coupon in the narrow sense that it bears no regular interest and does not accrete. It is not free of obligation. It leaves $3 billion of principal, conditional conversion rights, possible special interest, repurchase rights following a fundamental change and a fixed maturity.

The $392.62 cap belongs to a different contract

Moderna separately spent $328.8 million on capped calls with financial institutions. The filed confirmation form sets an initial strike of $210.5839 and a cap of $392.6175. The strike matches the note’s initial conversion economics, while the cap sits $182.0336 higher—an 86.44% band.

Those options cover, subject to adjustments, the initial shares underlying the notes. They are expected to reduce potential dilution or offset some cash due above principal on conversion. They do not change when a noteholder may convert, and they do not grant the holder a right at $392.62. The dealers owe performance to Moderna under separate contracts.

The distinction is visible in the mechanics. The capped calls are divided into components with separate expiry dates, use net-share settlement by default, allow other settlement choices under their terms and have a final termination date of 23 April 2032. Their payoff is bounded by the cap and can be affected by adjustments, early unwinds, market disruption and counterparty performance. The $392.62 line is therefore the upper boundary of an initial hedge formula, not a promise that dilution disappears below it.

Potential shares are a perimeter, not a prediction

At the initial conversion rate, the notes correspond to 14,246,100 shares. The 8-K also reports a maximum of 21,012,600 shares in limited circumstances. Moderna had 399,235,889 common shares outstanding on 24 July, according to its June-quarter 10-Q. The two potential counts equal 3.5683% and 5.2632% of that dated base.

Those percentages do not predict dilution. Cash settlement can avoid issuing some or all conversion shares while consuming liquidity; share settlement can conserve cash while enlarging the denominator. The capped calls cover the initial underlying count subject to adjustments, not automatically the maximum make-whole count. Anti-dilution provisions can also change the rates before any decision is made.

This is why a single “fully diluted” number would be false precision. The relevant receipt must state which conversion condition opened, how much principal moved, which settlement method Moderna chose, how the capped calls settled and what share denominator existed at that date.

The cash bridge is context, not the thesis

The pricing release initially described $2.6 billion of notes and a $400 million option. At completion, the $3 billion principal produced about $2.9573 billion of net proceeds after discounts, commissions and estimated expenses. After the $328.8 million capped-call purchase, approximately $2.6285 billion remained for general corporate purposes.

Moderna said those purposes may include oncology investment and debt repayment. “May” is not an allocation. At 30 June the company reported $6.910 billion of cash and investments, a $600 million secured term loan carrying about 9.20%, $900 million of undrawn delayed-draw commitments and a $950 million litigation settlement paid in July. These figures explain why financing flexibility matters, but they do not tell us which debt will be repaid or how much capital will go to any programme.

The cleaner monitoring object is the contract itself. Four stock-price lines and two major date gates allocate choice among holders, Moderna and hedge dealers. Treating them as one “conversion price” hides who can act.

Sources